We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Norovirus Interacts with Gut Bacteria to Establish a Persistent Infection That Can Be Blocked by Interferon Lambda

By LabMedica International staff writers
Posted on 27 Jan 2015
A team of molecular microbiologists and virologists has found that norovirus requires an intimate interaction with certain gut bacteria to establish a persistent infection, and that the infective process can be blocked by the immune factor interferon lambda (INFlambda).

Norovirus causes more than 90% of global epidemic nonbacterial gastroenteritis, and it is thought to be spread by a subset of people who maintain a low-level persistent infection. More...
How the enteric virus establishes such persistent infections is not well understood.

Investigators at Washington University School of Medicine (St. Louis, MO, USA) have turned up some interesting new insights regarding how norovirus infection becomes established and is maintained. They reported in the November 27, 2014, online edition of the journal Science that establishment of the viral infection in a mouse model depended on interaction with certain gut bacteria and that the infection could be prevented by treatment with antibiotics. Viral infection could be established following replenishment of the bacterial microbiota. Antibiotics did not prevent tissue infection or affect systemic viral replication, but acted specifically in the intestine.

In a second paper in the same issue of the journal Science, the investigators reported that while the cytokines interferon alpha (IFNalpha) and interferon beta (IFNbeta) prevented the systemic spread of norovirus in the mouse model, only IFNlambda controlled persistent enteric infection. Infection-dependent induction of IFNlambda was governed by the viral capsid protein and correlated with diminished enteric persistence. Treatment of established infection with IFNlambda cured mice in a manner that required non-hematopoietic cell expression of the IFNlambda receptor, Ifnlr1, and was independent of adaptive immunity.

“I believe that is a new concept in immunology,” said senior author Dr. Herbert W. Virgin, professor of pathology and immunology at Washington University School of Medicine. “We thought that interferon lambda and other related molecules in the immune system could only contain viral infections until other parts of the immune system, including antibodies and T-cells, finished the job.”

“The virus actually requires the bacteria to create a persistent infection,” said Dr. Virgin. “The virus appears to have a symbiotic relationship with the bacteria — they share the job of establishing persistence. We need a much more detailed understanding of how antibiotic treatment affects the links among host, bacteria, and virus.”

Related Links:

Washington University School of Medicine



Gold Member
Respiratory Syncytial Virus Test
OSOM® RSV Test
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
6 Part Hematology Analyzer with RET + IPF
Mispa HX 88
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.